A study of the impact of adding HPV types to cervical cancer screening and triage test

Mark Schiffman, Michelle J. Khan, Diane Solomon, Rolando Herrero, Sholom Wacholder, Allan Hildesheim, Ana Cecilia Rodriguez, Maria C. Bratti, Cosette M. Wheeler, Robert D. Burk

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Use of human papillomavirus (HPV) testing in cervical cancer prevention is increasing rapidly. A DNA test for 13 HPV types that can cause cervical cancer is approved in the United States for co-screening with cytology of women ≥30 years old and for triage of women of all ages with equivocal cytology. However, most infections with HPV are benign. We evaluated trade-offs between specificity and sensitivity for approximately 40 HPV types in predicting cervical intraepithelial neoplasia 3 and cancer in two prospective studies: a population-based screening study that followed 6196 women aged 30-94 years from Costa Rica for 7 years and a triage study that followed 3363 women aged 18-90 years with equivocal cytology in four U.S. centers for 2 years. For both screening and triage, testing for more than about 10 HPV types decreased specificity more than it increased sensitivity. The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer

Original languageEnglish (US)
Pages (from-to)147-150
Number of pages4
JournalJournal of the National Cancer Institute
Volume97
Issue number2
DOIs
StatePublished - Jan 19 2005

Fingerprint

Triage
Early Detection of Cancer
Uterine Cervical Neoplasms
Human Papillomavirus DNA Tests
Cell Biology
Costa Rica
Cervical Intraepithelial Neoplasia
Prospective Studies
Sensitivity and Specificity
Infection
Population
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A study of the impact of adding HPV types to cervical cancer screening and triage test. / Schiffman, Mark; Khan, Michelle J.; Solomon, Diane; Herrero, Rolando; Wacholder, Sholom; Hildesheim, Allan; Rodriguez, Ana Cecilia; Bratti, Maria C.; Wheeler, Cosette M.; Burk, Robert D.

In: Journal of the National Cancer Institute, Vol. 97, No. 2, 19.01.2005, p. 147-150.

Research output: Contribution to journalArticle

Schiffman, M, Khan, MJ, Solomon, D, Herrero, R, Wacholder, S, Hildesheim, A, Rodriguez, AC, Bratti, MC, Wheeler, CM & Burk, RD 2005, 'A study of the impact of adding HPV types to cervical cancer screening and triage test', Journal of the National Cancer Institute, vol. 97, no. 2, pp. 147-150. https://doi.org/10.1093/jnci/dji014
Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A et al. A study of the impact of adding HPV types to cervical cancer screening and triage test. Journal of the National Cancer Institute. 2005 Jan 19;97(2):147-150. https://doi.org/10.1093/jnci/dji014
Schiffman, Mark ; Khan, Michelle J. ; Solomon, Diane ; Herrero, Rolando ; Wacholder, Sholom ; Hildesheim, Allan ; Rodriguez, Ana Cecilia ; Bratti, Maria C. ; Wheeler, Cosette M. ; Burk, Robert D. / A study of the impact of adding HPV types to cervical cancer screening and triage test. In: Journal of the National Cancer Institute. 2005 ; Vol. 97, No. 2. pp. 147-150.
@article{7096908eee8a42f7940947be6b8c81d0,
title = "A study of the impact of adding HPV types to cervical cancer screening and triage test",
abstract = "Use of human papillomavirus (HPV) testing in cervical cancer prevention is increasing rapidly. A DNA test for 13 HPV types that can cause cervical cancer is approved in the United States for co-screening with cytology of women ≥30 years old and for triage of women of all ages with equivocal cytology. However, most infections with HPV are benign. We evaluated trade-offs between specificity and sensitivity for approximately 40 HPV types in predicting cervical intraepithelial neoplasia 3 and cancer in two prospective studies: a population-based screening study that followed 6196 women aged 30-94 years from Costa Rica for 7 years and a triage study that followed 3363 women aged 18-90 years with equivocal cytology in four U.S. centers for 2 years. For both screening and triage, testing for more than about 10 HPV types decreased specificity more than it increased sensitivity. The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer",
author = "Mark Schiffman and Khan, {Michelle J.} and Diane Solomon and Rolando Herrero and Sholom Wacholder and Allan Hildesheim and Rodriguez, {Ana Cecilia} and Bratti, {Maria C.} and Wheeler, {Cosette M.} and Burk, {Robert D.}",
year = "2005",
month = "1",
day = "19",
doi = "10.1093/jnci/dji014",
language = "English (US)",
volume = "97",
pages = "147--150",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A study of the impact of adding HPV types to cervical cancer screening and triage test

AU - Schiffman, Mark

AU - Khan, Michelle J.

AU - Solomon, Diane

AU - Herrero, Rolando

AU - Wacholder, Sholom

AU - Hildesheim, Allan

AU - Rodriguez, Ana Cecilia

AU - Bratti, Maria C.

AU - Wheeler, Cosette M.

AU - Burk, Robert D.

PY - 2005/1/19

Y1 - 2005/1/19

N2 - Use of human papillomavirus (HPV) testing in cervical cancer prevention is increasing rapidly. A DNA test for 13 HPV types that can cause cervical cancer is approved in the United States for co-screening with cytology of women ≥30 years old and for triage of women of all ages with equivocal cytology. However, most infections with HPV are benign. We evaluated trade-offs between specificity and sensitivity for approximately 40 HPV types in predicting cervical intraepithelial neoplasia 3 and cancer in two prospective studies: a population-based screening study that followed 6196 women aged 30-94 years from Costa Rica for 7 years and a triage study that followed 3363 women aged 18-90 years with equivocal cytology in four U.S. centers for 2 years. For both screening and triage, testing for more than about 10 HPV types decreased specificity more than it increased sensitivity. The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer

AB - Use of human papillomavirus (HPV) testing in cervical cancer prevention is increasing rapidly. A DNA test for 13 HPV types that can cause cervical cancer is approved in the United States for co-screening with cytology of women ≥30 years old and for triage of women of all ages with equivocal cytology. However, most infections with HPV are benign. We evaluated trade-offs between specificity and sensitivity for approximately 40 HPV types in predicting cervical intraepithelial neoplasia 3 and cancer in two prospective studies: a population-based screening study that followed 6196 women aged 30-94 years from Costa Rica for 7 years and a triage study that followed 3363 women aged 18-90 years with equivocal cytology in four U.S. centers for 2 years. For both screening and triage, testing for more than about 10 HPV types decreased specificity more than it increased sensitivity. The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer

UR - http://www.scopus.com/inward/record.url?scp=13744258937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744258937&partnerID=8YFLogxK

U2 - 10.1093/jnci/dji014

DO - 10.1093/jnci/dji014

M3 - Article

VL - 97

SP - 147

EP - 150

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -